The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2023

Filed:

Feb. 10, 2020
Applicant:

I-mab Biopharma Us Limited, Gaithersburg, MD;

Inventors:

Zhengyi Wang, Shanghai, CN;

Lei Fang, Shanghai, CN;

Bingshi Guo, Shanghai, CN;

Jingwu Zang, Shanghai, CN;

Assignee:

I-MAB, Grand Cayman, KY;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); C07K 16/40 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 9/006 (2013.01); A61K 9/0019 (2013.01); A61K 9/0031 (2013.01); A61K 9/0034 (2013.01); A61K 9/0043 (2013.01); A61K 9/06 (2013.01); A61K 35/17 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/2896 (2013.01); C07K 16/40 (2013.01); G01N 33/574 (2013.01); G01N 33/57407 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.


Find Patent Forward Citations

Loading…